NCI ETCTN Pittsburgh Cancer Consortium (PCC)

摘要 40多年来，国家癌症研究所(NCI)一直支持一项基础设施 在全美进行临床试验的计划。加强、促进和加快这一进程 在早期药物开发方面，NCI实施了一项全面计划，将 NCI赞助的早期临床试验计划，来自一系列独立的机构和努力 一项新的、巩固的、综合的计划，称为NCI实验治疗 临床试验网络(ETCTN)。UPMC希尔曼癌症中心(前身为华盛顿大学 匹兹堡癌症研究所，以下简称“肝细胞癌”)已被NCI指定为 综合性癌症中心自1990年以来，一直参与NCI早期药物 发展计划，自1999年以来。我们小组是入选的12个学术中心之一 第一阶段组件的ETCTN牵头学术组织(LAO)，以及随后 被选为10个学术中心之一，负责整合第二阶段临床试验工作 为成人癌症患者开发、领导和积累ETCTN临床试验。我们现在 建议成为NCI ETCTN的成员，担任匹兹堡癌症联盟(PCC)的负责人 学术组织与佛罗里达大学健康癌症中心和 阿尔伯特·爱因斯坦癌症中心。PCC的目标是创建一个统一、集成的临床 试验网络，将允许更无缝地推进和进步新的试验 通过药物开发的早期阶段的药物和/或组合。我们的最终目标是 该计划将极大地促进和加快向公民提供新的癌症治疗方法 宾夕法尼亚州、佛罗里达州中北部、纽约州布朗克斯市及其各自的集水区。

Abstract For more than 40 years, the National Cancer Institute (NCI) has supported an infrastructure program to conduct clinical trials across the US. To enhance, facilitate, and expedite the process of early-phase drug development, the NCI implemented a comprehensive plan transforming the NCI-sponsored early-phase clinical trials program from a series of separate institutions and efforts to a new, consolidated, integrated program, referred to as the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). The UPMC Hillman Cancer Center (formerly the University of Pittsburgh Cancer Institute, hereafter referred to as ‘HCC’) has been an NCI-designated comprehensive cancer center since 1990, and has been involved in the NCI Early Drug Development Program since 1999. Our group was one of 12 academic centers to be selected as an ETCTN Lead Academic Organization (LAO) for the phase 1 component, and subsequently selected as one of 10 academic centers to integrate phase 2 clinical trial efforts, with responsibility for developing, leading, and accruing to ETCTN clinical trials for adult cancer patients. We now propose to be a member of the NCI ETCTN as the Pittsburgh Cancer Consortium (PCC) Lead Academic Organization in a consortium with the University of Florida Health Cancer Center and the Albert Einstein Cancer Center. The goal of the PCC is to create a unified, integrated clinical trials network that will allow for more seamless advancement and progress of novel experimental agents and/or combinations through early stages of drug development. The eventual goal of our program is to greatly facilitate and accelerate the delivery of new cancer therapies to the citizens of Pennsylvania, North-Central Florida, Bronx, NY, and their respective catchment areas.